Based on the data retrieved from the TogoVar API, there is no mention of rs1057519999 being included in pharmacogenomics guidelines such as PharmGKB. The variant is associated with the TP53 gene and has been linked to various conditions, including hereditary cancer-predisposing syndromes and Li-Fraumeni syndrome, but no specific pharmacogenomic guidelines are provided in the retrieved data.

From external knowledge, TP53 is a well-studied tumor suppressor gene, and variants in TP53 are often associated with cancer predisposition rather than direct pharmacogenomic implications. However, TP53 variants can influence cancer treatment outcomes, particularly in therapies targeting p53 pathways. If you are looking for specific pharmacogenomic guidelines, consulting PharmGKB directly or other pharmacogenomic databases may be necessary.

### English Summary:
- **Pharmacogenomics Guidelines**: No specific mention of rs1057519999 in pharmacogenomics guidelines like PharmGKB in the retrieved data.
- **External Knowledge**: TP53 variants may indirectly influence cancer treatment outcomes but are not typically included in pharmacogenomic guidelines.

### Japanese Summary:
- **薬理ゲノミクスガイドライン**: TogoVar APIのデータには、rs1057519999がPharmGKBなどの薬理ゲノミクスガイドラインに含まれているという記載はありません。
- **外部知識**: TP53の変異は癌治療の結果に間接的に影響を与える可能性がありますが、通常は薬理ゲノミクスガイドラインには含まれていません。

#### Source URL:
- TogoVar: [https://togovar.org](https://togovar.org)